SEARCH

SEARCH BY CITATION

References

  • Ahrons, S., Glavind-Kristensen, S., Drachmann, O. & Kissmeyer-Nielsen, F. (1970) Severe reactions after cryoprecipitated human factor VIII. Vox Sanguinis, 18, 182184.
  • Alter, H.J. & Klein, H.G. (2008) The hazards of blood transfusion in historical perspective. Blood, 112, 26172626.
  • Atance, R., Pereira, A. & Ramirez, B. (2001) Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion, 41, 15481552.
  • Aygoren-Pursun, E., Martinez Saguer, I., Rusicke, E., Louwen, F., Geka, F., Ivaskevicius, V., Oldenburg, J., Klingebiel, T. & Kreuz, W. (2007) Retrochorionic hematoma in congenital afibrinogenemia: resolution with fibrinogen concentrate infusions. American Journal of Hematology, 82, 317320.
  • Aznar, J.A., Bonanad, S., Montoro, J.M., Hurtado, C., Cid, A.R., Soler, M.A. & De Miguel, A. (2000) Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. Vox Sanguinis, 79, 156160.
  • Balleisen, L., Bailey, J., Epping, P.H., Schulte, H. & Van De Loo, J. (1985) Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thrombosis and Haemostasis, 54, 475479.
  • Bevan, D.H. (1999) Cardiac bypass haemostasis: putting blood through the mill. British Journal of Haematology, 104, 208219.
  • Blome, M., Isgro, F., Kiessling, A.H., Skuras, J., Haubelt, H., Hellstern, P. & Saggau, W. (2005) Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thrombosis and Haemostasis, 93, 11011107.
  • Bronnimann, R. (1954) [Congenital afibrinogenemia; report of a case with multiple bone cysts and formation of a specific antibody (anti fibrinogen) following blood transfusion.]. Acta Haematologica, 11, 4051.
  • Bundesaertzekammer/German Medical Association. (2009) Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives, 4th edn. Available from: http://www.bundesaerztekammer.de/page.asp?his=0.6.3288.6716 (Accessed March 2010).
  • Cardigan, R., Philpot, K., Cookson, P. & Luddington, R. (2009) Thrombin generation and clot formation in methylene blue-treated plasma and cryoprecipitate. Transfusion, 49, 696703.
  • Chapman, C.E., Stainsby, D., Jones, H., Love, E., Massey, E., Win, N., Navarrete, C., Lucas, G., Soni, N., Morgan, C., Choo, L., Cohen, H. & Williamson, L.M. (2008) Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion, 49, 440452.
  • Charbit, B., Mandelbrot, L., Samain, E., Baron, G., Haddaoui, B., Keita, H., Sibony, O., Mahieu-Caputo, D., Hurtaud-Roux, M.F., Huisse, M.G., Denninger, M.H. & De Prost, D. (2007) The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. Journal of Thrombosis and Haemostasis, 5, 266273.
  • Chowdhury, P., Saayman, A.G., Paulus, U., Findlay, G.P. & Collins, P.W. (2004) Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. British Journal of Haematology, 125, 6973.
  • Ciavarella, D., Reed, R.L., Counts, R.B., Baron, L., Pavlin, E., Heimbach, D.M. & Carrico, C.J. (1987) Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. British Journal of Haematology, 67, 365368.
  • Coppola, L., Caserta, F., De Lucia, D., Guastafierro, S., Grassia, A., Coppola, A., Marfella, R. & Varricchio, M. (2000) Blood viscosity and aging. Archives of Gerontology and Geriatrics, 31, 3542.
  • Danes, A.F., Cuenca, L.G., Bueno, S.R., Mendarte Barrenechea, L. & Ronsano, J.B. (2008) Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sanguinis, 94, 221226.
  • De Vries, A., Rosenberg, T., Kochwa, S. & Boss, J.H. (1961) Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia. American Journal of Medicine, 30, 486494.
  • Dickneite, G., Joch, C. & Bergman, G.E. (2008) The evaluation of a prothrombotic risk in a human fibrinogen concentrate. Blood (American Society of Hematology Annual Meeting Abstracts), 112, 4064.
  • Dietrich, W. (2000) Cardiac surgery and the coagulation system. Current Opinion in Anaesthesiology, 13, 2734.
  • Elodi, S. & Varadi, K. (1979) Optimization of conditions for the catalytic effect of the factor IXa-factor VIII complex: probable role of the complex in the amplification of blood coagulation. Thrombosis Research, 15, 617629.
  • Fenger-Eriksen, C., Lindberg-Larsen, M., Christensen, A.Q., Ingerslev, J. & Sorensen, B. (2008) Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. British Journal of Anaesthesia, 101, 769773.
  • Fenger-Eriksen, C., Tonnesen, E., Ingerslev, J. & Sorensen, B. (2009a) Mechanisms of hydroxyethyl starch-induced dilutional coagulopathy. Journal of Thrombosis and Haemostasis, 7, 10991105.
  • Fenger-Eriksen, C., Midtgaard Jensen, T., Kristensen, B.S., Jensen, K.M., Tonnesen, E., Ingerslev, J. & Sorensen, B. (2009b) Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized placebo-controlled clinical trial. Journal of Thrombosis and Haemostasis, 7, 795802.
  • Fenger-Erikson, C., Ingerslev, J. & Sorenson, B. (2009c) Fibrinogen concentrate - a potential universal haemostatic agent. Expert Opinion on Biological Therapy, 9, 13251333.
  • Flamholz, R., Jeon, H.R., Baron, J.M. & Baron, B.W. (2000) Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? Journal of Clinical Apheresis, 15, 169172.
  • Fries, D., Innerhofer, P., Klingler, A., Berresheim, U., Mittermayr, M., Calatzis, A. & Schobersberger, W. (2002) The effect of the combined administration of colloids and lactated Ringer’s solution on the coagulation system: an in vitro study using thrombelastograph coagulation analysis (ROTEG). Anesthesia and Analgesia, 94, 12801287.
  • Fries, D., Krismer, A., Klingler, A., Streif, W., Klima, G., Wenzel, V., Haas, T. & Innerhofer, P. (2005) Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. British Journal of Anaesthesiology, 95, 172177.
  • Fries, D., Haas, T., Klingler, A., Streif, W., Klima, G., Martini, J., Wagner-Berger, H. & Innerhofer, P. (2006) Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy--a porcine model. British Journal of Anaesthesia, 97, 460467.
  • Gorlinger, K. (2006) Coagulation management during liver transplantation. Hamostaseologie, 26, S64S76.
  • Groner, A. (2008) Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. (Haematologica 2007;92:846-9). Haematologica, 93, e24e26.
  • Haas, T., Fries, D., Velik-Salchner, C., Oswald, E. & Innerhofer, P. (2008) Fibrinogen in craniosynostosis surgery. Anesthesia and Analgesia, 106, 725731.
  • Heim, M.U., Meyer, B. & Hellstern, P. (2009) Recommendations for the use of therapeutic plasma. Current Vascular Pharmacology, 7, 110119.
  • Heimburger, N. (2002) From cryoprecipitate to virus-safe high-purity concentrate. Seminars in Thrombosis and Hemostasis, 28(Suppl 1), 2530.
  • Heindl, B., Delorenzo, C. & Spannagl, M. (2005) [High dose fibrinogen administration for acute therapy of coagulopathy during massive perioperative transfusion]. Anaesthesia, 54, 787790.
  • Henkel-Honke, T. & Oleck, M. (2007) Artificial oxygen carriers: a current review. AANA Journal, 75, 205211.
  • Hiippala, S.T. (1995) Dextran and hydroxyethyl starch interfere with fibrinogen assays. Blood Coagulation & Fibrinolysis, 6, 743746.
  • Hiippala, S.T., Myllyla, G.J. & Vahtera, E.M. (1995) Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesthesia and Analgesia, 81, 360365.
  • Hornsey, V.S., Krailadsiri, P., MacDonald, S., Seghatchian, J., Williamson, L.M. & Prowse, C.V. (2000) Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma. British Journal of Haematology, 109, 665670.
  • Innerhofer, P., Fries, D., Margreiter, J., Klingler, A., Kuhbacher, G., Wachter, B., Oswald, E., Salner, E., Frischhut, B. & Schobersberger, W. (2002) The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesthesia and Analgesia, 95, 858865.
  • Ishikawa, S., Kario, K., Nago, N., Kayaba, K., Hiraoka, J., Matsuo, H., Goto, T., Miyamoto, T., Tsutsumi, A., Nakamura, Y., Shimada, K., Inoue, K. & Igarashi, M. (1997) Factor VII and fibrinogen levels examined by age, sex, and other atherosclerotic risk factors in a Japanese population. The Jichi Medical School Cohort Study. Thrombosis and Haemostasis, 77, 890893.
  • Josephson, C.D. & Abshire, T.C. (2006) Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease. Best Practice & Research. Clinical Haematology, 19, 3549.
  • Karlsson, M., Ternstrom, L., Hyllner, M., Baghaei, F., Nilsson, S. & Jeppsson, A. (2008) Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion, 48, 21522158.
  • Kestin, A.S., Valeri, C.R., Khuri, S.F., Loscalzo, J., Ellis, P.A., MacGregor, H., Birjiniuk, V., Ouimet, H., Pasche, B., Nelson, M.J., Benoit, S.E., Rodino, L.J., Barnard, M.R. & Michelson, A.D. (1993) The platelet function defect of cardiopulmonary bypass. Blood, 82, 107117.
  • Korte, W. & Feldges, A. (1994) Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. The Clinical Investigator, 72, 396398.
  • Kozek-Langenecker, S. (2007) Management of massive operative blood loss. Minerva Anestesiologica, 73, 401415.
  • Kreuz, W., Meili, E., Peter-Salonen, K., Haertel, S., Devay, J., Krzensk, U. & Egbring, R. (2005) Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfusion and Apheresis Science, 32, 247253.
  • Laharrague, P.F., Cambus, J.P., Fillola, G. & Corberand, J.X. (1993) Plasma fibrinogen and physiological aging. Aging (Milano), 5, 445449.
  • Lambrecht, B., Mohr, H., Knüver-Hopf, J. & Schmitt, H. (1991) Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sanguinis, 60, 207213.
  • Li, Y.F., Spencer, F.A. & Becker, R.C. (2001) Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition. American Heart Journal, 142, 204210.
  • MacLennan, S. & Barbara, J.A. (2006) Risks and side effects of therapy with plasma and plasma fractions. Best Practice & Research Clinical Haematology, 19, 169189.
  • Mardel, S.N., Saunders, F.M., Allen, H., Menezes, G., Edwards, C.M., Ollerenshaw, L., Baddeley, D., Kennedy, A. & Ibbotson, R.M. (1998) Reduced quality of clot formation with gelatin-based plasma substitutes. British Journal of Anaesthesia, 80, 204207.
  • Martini, W.Z., Pusateri, A.E., Uscilowicz, J.M., Delgado, A.V. & Holcomb, J.B. (2005) Independent contributions of hypothermia and acidosis to coagulopathy in swine. Journal of Trauma, 58, 10021009.
  • Mittermayr, M., Streif, W., Haas, T., Fries, D., Velik-Salchner, C., Klingler, A., Oswald, E., Bach, C., Schnapka-Koepf, M. & Innerhofer, P. (2007) Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesthesia and Analgesia, 105, 905917.
  • Mosesson, M.W. (2003) Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thrombosis and Haemostasis, 89, 912.
  • Nielsen, V.G., Cohen, B.M. & Cohen, E. (2005) Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta anaesthesiologica Scandinavica, 49, 222231.
  • Nizzi, F.A., Sapatnekar, S. & Blick, R.L. (2002) Hereditary coagulation protein defects. In: Disorders of thrombosis and haemostasis (ed. by R.L., Blick). pp. 117138. Lippincott Williams & Wilkins, Baltimore.
  • O’Shaughnessy, D.F., Atterbury, C., Bolton Maggs, P., Murphy, M., Thomas, D., Yates, S. & Williamson, L.M. (2004) Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. British Journal of Haematology, 126, 1128.
  • Oswald, M.W., Hunt, H.H. & Lazarchick, J. (1983) Normal range of plasma fibrinogen. The American Journal of Medical Technology, 49, 5759.
  • Pincock, S. (2004) Patient’s death from vCJD may be linked to blood transfusion. Committee to discuss need for further precautions to prevent possible vCJD transmission through blood. Lancet, 363, 43.
  • Pool, J.G. & Shannon, A.E. (1965) Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. New England Journal of Medicine, 273, 14431447.
  • Pool, J.G., Gershgold, E.J. & Pappenhagen, A.R. (1964) High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature, 203, 312.
  • Poon, M.C. (1993) Cryoprecipitate: uses and alternatives. Transfusion Medicine Reviews, 7, 180192.
  • Pothula, S., Sanchala, V.T., Nagappala, B. & Inchiosa, Jr, M.A.. (2004) The effect of preoperative antiplatelet/anticoagulant prophylaxis on postoperative blood loss in cardiac surgery. Anesthesia and Analgesia, 98, 410.
  • Ra’anani, P., Levi, Y., Varon, D., Gitel, S. & Martinowitz, U. (1991) [Congenital afibrinogenemia with bleeding, bone cysts and antibodies to fibrinogen]. Harefuah, 121, 291293.
  • Rahe-Meyer, N., Solomon, C., Winterhalter, M., Piepenbrock, S., Tanaka, K., Haverich, A. & Pichlmaier, M. (2009a) Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. Journal of Thoracic and Cardiovascular Surgery, 138, 694702.
  • Rahe-Meyer, N., Pichlmaier, M., Haverich, A., Solomon, C., Winterhalter, M., Piepenbrock, S. & Tanaka, K.A. (2009b) Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. British Journal of Anaesthesia, 102, 785792.
  • Reese, E.P., McCullough, J.J. & Craddock, P.R. (1975) An adverse pulmonary reaction to cryoprecipitate in a hemophiliac. Transfusion, 15, 583.
  • Reinhart, W.H. (2003) Fibrinogen–marker or mediator of vascular disease? Vascular Medicine, 8, 211216.
  • Rodriguez, R.C., Buchanan, G.R. & Clanton, M.S. (1988) Prophylactic cryoprecipitate in congenital afibrinogenemia. Clinical Pediatrics, 27, 543545.
  • Royston, D. & Von Kier, S. (2001) Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. British Journal of Anaesthesia, 86, 575578.
  • Seghatchian, J. & Krailadsiri, P. (2001) What’s happening? The quality of methylene blue treated FFP and cryo Transfusion and Apheresis Science, 25, 227231.
  • Shore-Lesserson, L., Manspeizer, H.E., DePerio, M., Francis, S., Vela-Cantos, F. & Ergin, M.A. (1999) Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesthesia and Analgesia, 88, 312319.
  • Spalding, G.J., Hartrumpf, M., Sierig, T., Oesberg, N., Kirschke, C.G. & Albes, J.M. (2007) Cost reduction of perioperative coagulation management in cardiac surgery: value of “bedside” thrombelastography (ROTEM). European Journal of Cardiothoracic Surgery, 31, 10521057.
  • Stainsby, D., MacLennan, S., Thomas, D., Isaac, J. & Hamilton, P.J. (2006) Guidelines on the management of massive blood loss. British Journal of Haematology, 135, 634641.
  • Stanworth, S.J. (2007) The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology. American Society of Hematology Educational Program, 2007, 179186.
  • Starr, D. (2002) Blood: An Epic History of Medicine and Commerce. Harper Collins, New York.
  • Stinger, H.K., Spinella, P.C., Perkins, J.G., Grathwohl, K.W., Salinas, J., Martini, W.Z., Hess, J.R., Dubick, M.A., Simon, C.D., Beekley, A.C., Wolf, S.E., Wade, C.E. & Holcomb, J.B. (2008) The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. The Journal of Trauma, 64, S79S85.
  • The Serious Hazards of Transfusion Steering Group. (2004) Serious Hazards of Transfusion Annual Report 2004. Available from: http://www.shotuk.org/SHOTREPORT2004.pdf (Accessed March 2010).
  • Ucar, H.I., Oc, M., Tok, M., Dogan, O.F., Oc, B., Aydin, A., Farsak, B., Guvener, M., Yorgancioglu, A.C., Dogan, R., Demircin, M. & Pasaoglu, I. (2007a) Preoperative fibrinogen levels as a predictor of postoperative bleeding after open heart surgery. The Heart Surgery Forum, 10, E392E396.
  • Ucar, H.I., Tok, M., Atalar, E., Dogan, O.F., Oc, M., Farsak, B., Guvener, M., Yilmaz, M., Dogan, R., Demircin, M. & Pasaoglu, I. (2007b) Predictive significance of plasma levels of interleukin-6 and high-sensitivity C-reactive protein in atrial fibrillation after coronary artery bypass surgery. The Heart Surgery Forum, 10, E131E135.
  • Velik-Salchner, C., Haas, T., Innerhofer, P., Streif, W., Nussbaumer, W., Klingler, A., Klima, G., Martinowitz, U. & Fries, D. (2007) The effect of fibrinogen concentrate on thrombocytopenia. Journal of Thrombosis and Haemostasis, 5, 10191025.
  • Wallis, J.P. (2003) Transfusion-related acute lung injury (TRALI)--under-diagnosed and under-reported. British Journal of Anaesthesia, 90, 573576.
  • Weinkove, R. & Rangarajan, S. (2008) Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfusion Medicine, 18, 151157.
  • Williamson, L.M., Cardigan, R. & Prowse, C.V. (2003) Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion, 43, 13221329.
  • World Federation of Hemophilia. (2005) Guidelines for the Management of Haemophilia. Available from: http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Gudelines_Mng_Hemophilia.pdf (Accessed March 2010).